Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus

American Journal of Health-System Pharmacy

Volumn 71, Issue 3, 2014, Pages 223-226

  Marino, Adriane B ^a   Cole, Sabrina W ^a   Nuzum, Donald S ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; LIRAGLUTIDE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1;

ADVERSE OUTCOME; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; DYSPEPSIA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; INSULIN RELEASE; LONG TERM CARE; MEDICATION COMPLIANCE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PATIENT COMPLIANCE; ARTICLE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; NAUSEA;

EID: 84906814117     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130301     Document Type: Note

References (14)

1. Victoza (liraglutide) package insert. Princeton, NJ: Novo Nordisk A/S; 2012.
2. King A, Wolfe G. Accuracy of dosage volume for halfway doses in the Victoza pen. J Diabetes Sci Technol. 2011; 5:1623-4.
3. Shaw MM, Brandle M, Bebakar WM et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26:268-78.
4. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combina tion with metformin, in type 2 diabetes. Diabetes Care. 2009; 32:84-90.
5. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373:473-81.
6. Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009; 32:1224-30.
7. Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomized controlled trial. Diabetologia. 2009; 52:2046-55.
8. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374:39-47.
9. Garber AJ. Long-acting glucagon-like peptide-1 receptor agonists. Diabetes Care. 2011; 34(suppl 2):S279-84.
10. Ryan GJ, Foster KT, Jobe LJ. Review of the therapeutic uses of liraglutide. Clin Ther. 2011; 33:793-811.
11. Byetta (exenatide) package insert. San Diego, CA: Amylin Pharmaceuticals; 2007.
12. Bydureon (exenatide long-acting release) package insert. San Diego, CA: Amylin Pharmaceuticals; 2012.
13. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care. 2013; 36(suppl 1):S11-66.
14. American Association of Clinical Endocrinologists. 2013 Comprehensive diabetes management algorithm. Endocrine Practice. 2013; 19:327-36.